-
Cell Cycle Assay Kit for Leukemia Research
2026-08-24
Turn DNA content into an actionable map of cell cycle arrest, replication, and apoptosis in leukemia and other disease models. This workflow combines PI/RNase A staining with singlet-aware flow cytometry and troubleshooting strategies for more defensible cell cycle progression analysis.
-
CX-4945 (Silmitasertib): CK2 to Translation
2026-08-23
CX-4945 (Silmitasertib) offers a mechanistically defined route to interrogate CK2-dependent survival, cell-cycle, and inflammatory signaling. This thought-leadership analysis connects established oncology workflows with emerging evidence that CSNK2A1/CK2 contributes to post-ischemic neuroinflammation, while separating validated findings from translational hypotheses.
-
Annexin V-APC/7-AAD in Epigenetic Therapy
2026-08-22
A translational framework for using the Annexin V-APC/7-AAD Apoptosis Kit to connect epigenetic drug response with phosphatidylserine exposure, membrane integrity, and mechanistic validation in MLL-rearranged leukemia models.
-
GDC-0068 Workflow for PI3K/Akt/mTOR Assays
2026-08-21
GDC-0068 (RG7440) offers a practical pan-AKT perturbation strategy for genotype-aware cancer signaling assays. This workflow connects dose response, phosphosite interpretation, cell-fate measurements, and spatial mTORC1 questions while highlighting formulation and troubleshooting choices that improve reproducibility.
-
TG003 Cdc2-like Kinase Inhibitor: Workflow Guide
2026-08-20
TG003 enables rapid, reversible control of Clk-dependent serine/arginine-rich protein phosphorylation for alternative splicing and exon-skipping experiments. This workflow also shows how to test Clk2-linked platinum resistance while separating family-wide pharmacology from gene-specific conclusions.
-
MK-2206 Dihydrochloride: Akt Assay Workflows
2026-08-20
Build cleaner Akt-pathway experiments with MK-2206 dihydrochloride, from phosphorylation time courses to apoptosis and drug-combination studies. The workflow also shows how to use Akt inhibition as a mechanistic control when studying Wnt-driven glycolysis and osteoblast differentiation.
-
TBXA2R–ERM Signaling in TNBC Metastasis
2026-08-19
The reference study identifies TBXA2R as a GPCR that activates ezrin, radixin, and moesin through coordinated G-protein, Rho GTPase, and kinase signaling. This TBXA2R–ERM axis promotes triple-negative breast cancer cell motility, invasion, and metastatic colonization, providing a mechanistic link between receptor signaling and the cytoskeletal programs that support metastasis.
-
Flubendazole: Translational Autophagy Strategy
2026-08-19
A thought-leadership perspective on using Flubendazole to connect autophagy biology with metabolic state, assay rigor, and translational decision-making across cancer, fibrosis, and neurodegeneration research.
-
AZD8055: Practical mTOR Inhibition Workflow
2026-08-18
AZD8055 is an ATP-competitive mTOR inhibitor for controlled studies of mTORC1 and mTORC2 signaling, cancer cell proliferation, and metabolism. It is appropriate for mechanistic preclinical workflows, but its aqueous insolubility, formulation requirements, and limited clinical benefit make it unsuitable for inferring clinical efficacy without independent evidence.
-
GDC-0068 Workflow for Spatial Akt–mTORC1 Studies
2026-08-18
GDC-0068 (RG7440) provides a selective, pan-AKT perturbation strategy for connecting PI3K/Akt signaling to proliferation, cell-cycle control, and mTORC1 outputs. This workflow pairs rapid phospho-signaling measurements with compartment-aware assays inspired by the latest nuclear mTORC1 research.
-
Tetrahydromagnolol: CB2 Assay Workflows
2026-08-17
Tetrahydromagnolol enables receptor-proximal CB2 activation studies while its GPR55 antagonism creates a useful specificity challenge. This workflow connects cannabinoid pharmacology with inflammation, analgesic signaling, and carefully controlled cell-motility assays inspired by recent TNBC metastasis research.
-
Actinomycin D as a Transcriptional Logic Probe
2026-08-17
Actinomycin D can do more than trigger cytotoxicity: it can help distinguish altered transcription from mRNA decay in pancreatic cancer models. This article connects ActD transcriptional shutoff assays with the OTUB1–DDX3X–DHODH mechanism of gemcitabine resistance and translates that biology into practical experimental decisions.
-
CHK1 Inhibition in Breast Cancer: ER/PR-Dependent Effects
2026-08-16
This study shows that CHK1 inhibition has opposing therapeutic implications across receptor-defined breast cancer subtypes. It enhances adriamycin sensitivity in ER−/PR−/HER2− models but produces single-agent activity, rather than chemosensitization, in ER+/PR+/HER2− cells, providing a rationale for biomarker-guided CHK1 targeting.
-
Carvedilol Workflows for β-Receptor Research
2026-08-15
Carvedilol enables integrated studies of β- and α1-adrenergic signaling, oxidative stress, vascular remodeling, and post-transplant hematopoietic recovery. This workflow-focused guide connects concentration selection, controls, comparative β-blocker experiments, and troubleshooting to the latest evidence on regeneration after hematopoietic cell transplantation.
-
Tetrahydromagnolol: A Translational CB2 Lens
2026-08-14
Tetrahydromagnolol offers a defined pharmacology platform for peripheral CB2 receptor agonism, GPR55 antagonism, and mechanism-led translational studies. This article connects its cannabinoid signaling profile with the TBXA2R–ERM metastasis study while distinguishing evidence-based rationale from hypotheses that still require validation.